Research Pulse — 2026-10-03 | Brown Biotech

# Research Pulse — 2026-10-03
_Generated 2026-10-03 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 10월 3일 (금요일) · Converging(수렴) Day**

10/03(수렴) → 9/30(번역) → 9/29(안착) → 9/28(제도화) → 9/27(성숙) → 9/26(확장) → 9/25(시너지) → 9/24(집적화). Translating(9/30) + Embedding(9/29)된 기술들이 **수렴(Converging)의 단계로 이행하며, 여러 영역에서 동시적 수렴 검증(Regulatory-grade monitoring × Clinical validation × Head-to-head benchmarking × AI/ML regulatory integration)이 일어나는 날** — Şahin et al.로 CRISPR global clinical trajectory — ClinicalTrials.gov+EUCTR注册的 2026년 9월 기준update + 제약사-CRO Academic partnership + EU COST GenE-HumDi 협력 체계화(Molecular Therapy Nucleic Acids 2026), Freedman et al.로 somatic cell genome editing monitoring toolkit — nucleotides→organism whole-scale + microphysiological systems + non-invasive imaging + regulatory-grade assessment (Nature Reviews Genetics 2026), Yoo et al.로 TNIK inhibitor Phase IIa efficacy validation — AI-designed molecule의 clinical translation milestone + broader validation·mechanistic understanding 필요성(BJC Reports 2026), Lin et al.로 AlphaFold2/3 oligomeric state prediction — 4,700+ proteins 검증 + training data dependency boundary + reliable predictions majority (Protein Science 2026), Wang et al.로 SCMBench 23 methods benchmarking — FMs fall short of DMs + lightweight adaptation strategy + domain-specific model 우위 실증(Nature Communications 2026), Cervilla et al.로 spatial transcriptomics 5 platforms benchmarking — Visium v1/v2/HD + Xenium + CosMx + FFPE clinical samples + head-to-head comparison (Genome Biology 2026), Oo et al.로 FDA platform-aligned + AI/ML analytics — dose selection·safety evaluation·durability prediction의 regulatory-grade convergence (J Clinical Pharmacology 2026)가 동시에 진행된다.

Converging은 Translating의 다음 단계다. 오늘 6개 전선은 번역된 기술들이 **동시적 수렴 검증(Regulatory-grade × Clinical validation × Head-to-head benchmarking)을 경험하며, 기술의 실용성이 다차원적으로 확인되는 수렴의 날**이다.

*출처: [Şahin CRISPR Global Trajectory Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/), [Freedman Genome Editing Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Yoo TNIK Inhibitor Phase IIa BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Lin AlphaFold Oligomeric State Protein Science 2026](https://consensus.app/papers/details/cff9b03d33d85cdf8d04f175b025a42c/), [Wang SCMBench Single-Cell Multi-Omics Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cervilla Spatial Platforms Benchmarking Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Oo FDA Platform AI Analytics J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)*

*#ConvergingDay #Şahin #CRISPR #MolecularTherapy #ClinicalTrials #GlobalTrajectory #GenEHumDi #Freedman #NatureReviewsGenetics #Monitoring #GenomeEditing #Yoo #TNIK #PhaseIIa #BJCReports #Lin #ProteinScience #AlphaFold #OligomericState #Wang #SCMBench #NatureCommunications #FoundationModel #DomainSpecific #Cervilla #GenomeBiology #SpatialTranscriptomics #Benchmarking #FFPE #Oo #FDA #PlatformAligned #AI #ML #Analytics #Converging #ClinicalValidation #Benchmarking #RegulatoryGrade #BiomedicalAI #DailyReport*

---

### Post 2: CRISPR & Gene Editing — Global Clinical Trajectory × Regulatory-Grade Monitoring: Converging

🪄 **[CRISPR/Gene Editing] Şahin et al.로 CRISPR global clinical trajectory — ClinicalTrials.gov+EUCTR注册的 2026년 9월 기준update + 제약사-CRO academic partnership + EU COST GenE-HumDi 체계화(Molecular Therapy Nucleic Acids 2026) + Freedman et al.로 somatic cell genome editing monitoring toolkit — nucleotides→organism whole-scale + microphysiological systems + non-invasive imaging + regulatory-grade assessment (Nature Reviews Genetics 2026) + Chakraborty et al.로 Casgevy approval landscape + UKMHRA/FDA approval + industry-academia collaboration + patent landscape 종합(Trends in Biotechnology 2026): CRISPR Converging(수렴) 동시 확인**

CRISPR gene therapy의 **global clinical trajectory 수렴 + regulatory-grade monitoring 체계화(Converging)**가 출처에서 동시에 확인된다[1][2][3].

Ceren Şahin et al.(Molecular Therapy. Nucleic Acids 2026)의 연구는 CRISPR 치료제의 글로벌 임상 시험 현주소를 종합한다[1]. ClinicalTrials.gov와 EU Clinical Trials Register 등록 시험을 체계적으로 분석하여 2026년 9월 기준 글로벌 CRISPR 치료제 임상 활동 현황을 제시한다. 제약사-CRO academic partnership의 협력 체계와 EU COST action GenE-HumDi의跨国 협력 프레임워크를 정리한다. broad clinical application을 저해하는 technical·regulatory·manufacturing·economic challenges를 체계적으로 분석한다.

Benjamin S. Freedman et al.(Nature Reviews Genetics 2026)의 review는 somatic cell genome editing의 biological effects를 모니터링하는 도구 키트를 제시한다[2]. nucleotide 단위 측정에서 whole organism 단위까지 다양한 biological scales를 포괄하는 모니터링 전략을 제시한다. microphysiological systems(organs-on-chips, organoids)로 phenotypic 평가가 가능하며, non-invasive imaging으로 in vivo biodistribution과 genome editor activity 추적이 가능하다. on-target과 off-target editing outcomes의 직접 측정이 가능하며, regulatory-grade safety and efficacy assessment를 위한 comprehensive toolkit을 제공한다. translational preclinical-to-clinical bridging을 실현한다.

Chakraborty et al.(Trends in Biotechnology 2026)의 review는 Casgevy(CRISPR-Cas9 치료제)의 regulatory approval landscape를 종합한다[3]. UKMHRA 2023년 11월 TDT 승인 → UKMHRA SCD 승인 → FDA 2023년 12월 승인까지의 approval trajectory를 분석한다. biopharmaceutical industry-academia collaboration과 patent landscape를 정리하며, challenges·safety concerns·cost-effectiveness를 종합한다.

9월 30일 Translating(Magdy exagamglogene + kayjayguran on/off-target + du Rand EB therapy) vs 오늘의 차별점: 9/30이 Magdy Trends Biotechnology으로 exagamglogene + kayjayguran의 on/off-target 활동 스펙트럼 + 규제 심사 프레임워크를, du Rand Drugs으로 EB에서의 Cas9 nickases + prime editing을 제시했다면, 오늘은 Şahin Molecular Therapy으로 ClinicalTrials.gov+EUCTR注册的 2026년 9월 기준update 글로벌 임상 시험 trajectory를(수렴된 임상 데이터), Freedman Nature Reviews Genetics으로 nucleotides→organism whole-scale regulatory-grade monitoring toolkit을(수렴된 안전성 평가), Chakraborty Trends Biotechnology으로 Casgevy UKMHRA→FDA approval trajectory + patent landscape를(수렴된 규제 체계) 동시에 제시한다. Translating(9/30) → clinical trajectory + regulatory monitoring + approval landscape Converging(10/03).

실무 함의: 유전자 치료 개발팀에서 Freedman et al.의 regulatory-grade monitoring toolkit을 참조하여 preclinical-to-clinical bridging 전략을 수립해야 한다.

*출처: [Şahin CRISPR Global Trajectory Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/), [Freedman Genome Editing Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Chakraborty CRISPR Casgevy Landscape Trends Biotechnology 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)*

*#CRISPR #GeneEditing #Şahin #MolecularTherapyNucleicAcids #ClinicalTrials #EUCTR #GenEHumDi #COST #GlobalTrajectory #Freedman #NatureReviewsGenetics #GenomeEditing #Monitoring #MicrophysiologicalSystems #Organoids #OrgansOnChips #NonInvasiveImaging #RegulatoryGrade #Chakraborty #TrendsBiotechnology #Casgevy #UKMHRA #FDA #Approval #Patent #IndustryAcademia #ConvergingDay #ClinicalValidation #RegulatoryFramework #BiomedicalAI #DailyReport*

---

### Post 3: AI 신약 — TNIK Phase IIa Efficacy Validation × Preclinical Pipeline Convergence: Converging

💊 **[AI 신약] Yoo et al.로 TNIK inhibitor Phase IIa efficacy validation — AI-designed molecule clinical translation milestone + adaptive data-informed drug discovery + federated model validation + precision oncology 적용(BJC Reports 2026) + Mao et al.로 AI drug discovery clinical translation 현황 — Phase IIa efficacy + Phase I safety stop + 0건 완전 AI 승인 현실 + algorithmic transparency + data quality (Frontiers in Pharmacology 2026) + Cai et al.로 preclinical AI pipeline 종합 — multimodal AI + digital twins + closed-loop automation + regulatory adaptation (Pharmaceuticals 2026): AI drug discovery Converging(수렴) 동시 확인**

AI-Driven Drug Discovery의 **clinical translation efficacy validation + preclinical pipeline convergence(Converging)**가 출처에서 동시에 확인된다[4][5][6].

Wonbeak Yoo et al.(BJC Reports 2026)의 perspective는 AI-designed TNIK inhibitor의 Phase IIa efficacy를 분석한다[4]. AI로 설계된 TNIK inhibitor가 idiopathic pulmonary fibrosis 환자에서 Phase IIa trial에서 efficacy를 확인했다. safety·tolerability·pharmacodynamic target engagement가 확인되었으며, functional decline 감소 경향이 나타났다. AI-derived molecules가 human testing 진입 가능성을 입증했으나, broader validation·mechanistic understanding·regulatory alignment가 필요하다. adaptive data-informed drug discovery와 federated model validation 전략을 제시하며, precision oncology 적용 가능성을 논의한다.

Zihan Mao et al.(Frontiers in Pharmacology 2026)의 review는 AI drug discovery의 임상 번역 현황을 종합한다[5]. AI候补 Phase IIa에서 encouraging efficacy를 보인 첫 성과와 Phase I에서 safety signals로 정지된候补이 동시에 존재한다. 완전 AI 발견/설계 약물의 마케팅 승인은 0건이다. AI 독성 earlier 단계 detection이 가능하나 완전히 elimination은 불가하며, biological complexity·patchy data·ML+pharmaceutics 인력 부족이 원인이다. algorithmic transparency와 data quality가 규제 수용성 조건으로 작용한다.

Meng Cai et al.(Pharmaceuticals 2026)의 review는 preclinical AI pipeline을 종합한다[6]. drug-target interaction prediction, structure prediction, de novo design, virtual screening, drug repurposing, ADMET forecasting의 6개 단계를 포괄한다. multimodal AI, digital twins, closed-loop automation이 미래 방향으로 제시되며, regulatory adaptation 필요성이 강조된다. data quality, model interpretability, patient heterogeneity, regulatory adaptation이 핵심 translational hurdles로 분석된다.

9월 30일 Translating(Herdiana disruptive force + Ali clinical translation + Seyhan 3D molecular design) vs 오늘의 차별점: 9/30이 Herdiana Drug Design으로 규제·데이터·인력 번역 장벽 체계화를, Ali Drug Development Research으로 target ID에서 clinical translation 현황을, Seyhan Biomedicines으로 3D molecular design 도구를 제시했다면, 오늘은 Yoo BJC Reports으로 TNIK inhibitor Phase IIa efficacy validation이라는 구체적 clinical milestone을(수렴된 임상 데이터), Mao Frontiers Pharmacology으로 Phase IIa + Phase I 동시 현실 + 0건 완전 승인 체계화를(수렴된 현황 평가), Cai Pharmaceuticals으로 preclinical pipeline 종합 + regulatory adaptation 필요성을(수렴된 파이프라인) 동시에 제시한다. Translating(9/30) → clinical efficacy validation + pipeline convergence Converging(10/03).

실무 함의: AI drug discovery 팀에서 Yoo et al.의 TNIK Phase IIa 결과를 참조하여 AI候补 임상 전략을 수립해야 한다.

*출처: [Yoo TNIK Inhibitor Phase IIa BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Mao AI Drug Discovery Clinical Translation Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Cai Preclinical AI Pipeline Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/)*

*#AI #DrugDiscovery #Yoo #BJCReports #TNIK #PhaseIIa #Efficacy #IPF #IdiopathicPulmonaryFibrosis #AdaptiveTrial #FederatedModel #PrecisionOncology #Mao #FrontiersinPharmacology #PhaseI #Safety #ZeroAIApproval #ClinicalTranslation #Cai #Pharmaceuticals #Preclinical #MultimodalAI #DigitalTwins #ClosedLoopAutomation #RegulatoryAdaptation #ConvergingDay #ClinicalValidation #PipelineIntegration #BiomedicalAI #DailyReport*

---

### Post 4: 단백질 AI — AlphaFold Oligomeric 4,700+ Proteins × SCMBench 23 Methods Benchmarking: Converging

🔬 **[단백질 AI] Lin et al.로 AlphaFold2/3 oligomeric state prediction — 4,700+ proteins 분석 + reliable predictions majority + training data dependency boundary + multiple physiologically relevant assemblies (Protein Science 2026) + Wang et al.로 SCMBench 23 methods benchmarking — FMs fall short of DMs + lightweight adaptation strategy + domain-specific model 우위 실증(Nature Communications 2026) + Sarti et al.로 AlphaFold quality arity map — whole proteome + physically implausible predictions flagging + Arity-Q scoring (Bioinformatics Advances 2026): 단백질 AI Converging(수렴) 동시 확인**

단백질 AI의 **oligomeric state prediction 4,700+ proteins 대규모 검증 + FM vs DM 성능 격차 benchmarking(Converging)**이 출처에서 동시에 확인된다[7][8][9].

Yiechang Lin et al.(Protein Science 2026)의 연구는 AlphaFold2-Multimer와 AlphaFold3의 oligomeric state prediction 정확도를 4,700개 이상의 단백질에서 체계적으로 평가한다[7]. majority of cases에서 reliable predictions을 제공하며, training data에 close structural representatives가 없는 경우 정확도가 제한된다는 boundary를 제시한다. multiple physiologically relevant assemblies가 가능한 일부 단백질을 확인했으며, computational cost 최소화 전략과 challenging cases identification 방법을 제공한다. AlphaFold-based oligomeric state prediction의 utility와 current limitations을 모두 확인했다.

Yixuan Wang et al.(Nature Communications 2026)의 연구는 SCMBench로 23개 방법의 성능을 benchmarking한다[8]. 23개 방법을 integration accuracy, biomarker detection, trajectory inference, batch effect correction에서 평가했으며, foundation models가 domain-specific models보다 낮은 성능을 보인다는 결과를 실증했다. lightweight adaptation strategy로 FM 성능 향상을 제시하며, domain-specific model 우위를 실증적으로 확인했다.

Edoardo Sarti et al.(Bioinformatics Advances 2026)의 연구는 AlphaFold predictions의 whole proteome 차원 품질 평가를 위한 arity map 방법을 제시한다[9]. well-folded proteins, intrinsically disordered proteins, physically implausible predictions의 세 가지 구조적 집단으로 분류하며, Arity-Q scoring function으로 hallucinated helices와 distorted beta strands를 flagging한다. pLDDT 한계를 극복하며 native-like predictions를 올바르게 scoring한다.

9월 30일 Translating(Fadini ROCKET + Wang SCMBench) vs 오늘의 차별점: 9/30이 Fadini Nature Methods으로 ROCKET AlphaFold2 + cryo-EM 통합을, Wang Nature Communications으로 SCMBench FM vs DM 성능 격차를 제시했다면, 오늘은 Lin Protein Science으로 AlphaFold oligomeric state prediction을 4,700+ proteins에서 대규모 검증한 구체적 정확도 boundary를(수렴된 검증), 같은 Wang SCMBench에서 lightweight adaptation strategy를 통한 FM 성능 향상 전략을(수렴된 벤치마크), Sarti Bioinformatics Advances으로 whole proteome quality assessment 표준 프레임워크를(품질 체계화) 동시에 제시한다. Translating(9/30) → 4,700+ proteins 검증 + benchmarking + quality framework Converging(10/03).

실무 함의: 단백질 구조 연구팀에서 Lin et al.의 oligomeric state prediction boundary를 참조하여 AlphaFold 예측 신뢰성 평가 전략을 수립해야 한다.

*출처: [Lin AlphaFold Oligomeric State Protein Science 2026](https://consensus.app/papers/details/cff9b03d33d85cdf8d04f175b025a42c/), [Wang SCMBench Single-Cell Multi-Omics Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Sarti AlphaFold Quality Arity Map Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/)*

*#ProteinAI #AlphaFold #Lin #ProteinScience #OligomericState #4700Proteins #TrainingData #ReliablePredictions #Wang #SCMBench #NatureCommunications #FoundationModel #DomainSpecific #Benchmarking #23Methods #LightweightAdaptation #Sarti #BioinformaticsAdvances #ArityMap #QualityAssessment #ArityQ #PhysicallyImplausible #ConvergingDay #Validation #Benchmarking #AccuracyBoundary #BiomedicalAI #DailyReport*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — SCMBench Benchmarking × Platform Convergence: Converging

🬬 **[Single-Cell Multi-Omics Foundation Model] Wang et al.로 SCMBench 23 methods benchmarking — FMs fall short of DMs + lightweight adaptation strategy + domain-specific model 우위 실증(Nature Communications 2026) + Ji et al.로 CAPTAIN multimodal FM — scRNA + 382 proteins + cross-modality dependencies + COVID-19 immune patterns (Nature Communications 2026) + Cen et al.로 single-cell + spatial omics comprehensive review — AI + foundation models + multi-omics integration algorithms + translational gap (MedComm 2026): foundation model Converging(수렴) 동시 확인**

Single-Cell Foundation Model의 **FM vs DM 성능 격차 benchmarking + multimodal integration convergence(Converging)**가 출처에서 동시에 확인된다[8][10][11].

Yixuan Wang et al.(Nature Communications 2026)의 SCMBench 연구는 foundation model의 한계를 실증한다[8]. 23개 방법 benchmarking에서 foundation models가 domain-specific models보다 낮은 성능을 보였으며, lightweight adaptation strategy로 FM 성능 향상을 제시한다. integration accuracy, biomarker detection, trajectory inference, batch effect correction의 4개 차원에서 평가했으며, cellular characteristics preservation, transcriptomic biomarkers, epigenomic regulatory elements, development trajectories의 holistic analysis를 수행했다. FMs fall short of state-of-the-art DMs라는 결론을 실증적으로 확인했다.

Boya Ji et al.(Nature Communications 2026)의 CAPTAIN 연구는 multimodal foundation model의 integration을 보여준다[10]. 4 million 이상의 단일세포에서 transcriptomes와 382개의 surface proteins를 동시 측정했으며, unified multimodal representations를 생성한다. protein imputation과 expansion, cell type annotation, batch harmonization에서 superior downstream performance를 보이며, COVID-19 severity 관련 immune interaction patterns이라는 novel biology를 발견했다. cross-modality dependencies learning으로 modality 간 의존성을 학습한다.

Xiaoping Cen et al.(MedComm 2026)의 review는 single-cell + spatial omics의 현재 현황을 종합한다[11]. 단일세포 + 공간 전사체 기술이 고해상도 분자 프로파일링을 실현하며, AI와 foundation models가 급속히 발전하고 있다. multi-omics integration algorithms 현황과 biomarker discovery, therapeutic target identification 적용 사례를 정리하며, technological innovation과 biomedical discovery 사이의 translational gap을 지적했다.

9월 30일 Translating(Ji CAPTAIN 382 proteins + Wang SCMBench + Cen comprehensive review) vs 오늘의 차별점: 9/30이 Ji Nature Communications으로 CAPTAIN multimodal을, Wang Nature Communications으로 SCMBench benchmarking을, Cen MedComm으로 comprehensive review를 제시했다면, 오늘은 같은 Wang SCMBench에서 lightweight adaptation strategy라는 구체적 FM 성능 향상 전략을(벤치마크 체계화), 같은 Ji CAPTAIN에서 COVID-19 severity 관련 구체적 biology discovery를(발견 수렴), Cen MedComm에서 기술→발견 translational gap 지적을(수렴 장벽 분석) 동시에 제시한다. Translating(9/30) → benchmarking strategy + biology discovery + gap analysis Converging(10/03).

실무 함의: 단일세포 연구팀에서 Wang et al.의 SCMBench 결과를 참조하여 foundation model vs domain-specific model 선택 기준을 수립해야 한다.

*출처: [Wang SCMBench Single-Cell Multi-Omics Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Ji CAPTAIN Multimodal Foundation Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Cen Single-Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)*

*#SingleCell #FoundationModel #Wang #SCMBench #NatureCommunications #FoundationModel #DomainSpecific #Benchmarking #23Methods #LightweightAdaptation #IntegrationAccuracy #BiomarkerDetection #Ji #CAPTAIN #Multimodal #NatureCommunications #382Proteins #CrossModality #COVID19 #ImmunePatterns #Cen #MedComm #SpatialOmics #ComprehensiveReview #TranslationalGap #ConvergingDay #Benchmarking #PerformanceGap #BiomedicalAI #DailyReport*

---

### Post 6: FDA/규제 — AI/ML Regulatory Analytics × Platform-Aligned Convergence: Converging

📋 **[FDA/규제] Oo et al.로 FDA gene therapy approvals platform-aligned + AI/ML analytics — dose selection·safety evaluation·durability prediction convergence + plausible mechanism + CMC flexibility (J Clinical Pharmacology 2026) + Shahzad et al.로 FDA CGT 38개 approval assessment — 86.8% orphan + 92.1% expedited + 73.7% single study + 44.7% surrogate + 73.4% PMR/PMC (Clinical Pharmacology 2026) + Sheikh et al.로 Kresladi FDA approval March 2026 — LAD-I gene therapy 구체적 제품화 + hematopoietic stem cell 유전자 편집 (Annals of Medicine 2026): FDA/규제 Converging(수렴) 동시 확인**

FDA/규제의 **AI/ML analytics regulatory integration + platform-aligned convergence(Converging)**가 출처에서 동시에 확인된다[12][13][14].

C. Oo et al.(J Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals의 evolvolution과 regulatory framework를 분석한다[12]. FDA의 platform-aligned, risk-based initiatives — plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program을 정리한다. AI/ML-enabled analytics가 dose selection, safety evaluation, durability prediction에서日益 적용되고 있음을 확인한다. individualized, mechanistically targeted, potentially curative products 지원을 위한 regulatory framework의 발전을 분석한다.

Mahnum Shahzad et al.(Clinical Pharmacology & Therapeutics 2026)의 연구는 FDA CGT 38개 승인의 evidence profile을 분석한다[13]. 86.8% orphan designation, 92.1% expedited pathway, 73.7% single pivotal study, 44.7% surrogate endpoints exclusively, 73.4% PMR/PMC라는 구체적 수치를 제시한다. 17.9%만 primary clinical efficacy endpoint를 포함하며, 대부분의 연구가 ongoing 상태다. timely access 우선과 limited premarket data 의존의 tradeoff를 지적한다.

M. Sheikh et al.(Annals of Medicine and Surgery 2026)의 연구는 Kresladi FDA 승인을 분석한다[14]. Leukocyte Adhesion Deficiency-I(LAD-I) 치료를 위한 유전자 치료제로, 2026년 3월 26일 FDA 승인을 받았다. ITGB2 유전자 편집으로 환자 자신의 조혈줄기세포를 유전자 편집하여 ITGB2 발현을 회복한다. HLA 일치 형제 기증자 없는 LAD-I 소아 환자 치료용으로 승인되었다.

9월 30일 Translating(Magdy CRISPR on/off-target + Herdiana disruptive force + Ali algorithmic transparency) vs 오늘의 차별점: 9/30이 Magdy Trends Biotechnology으로 CRISPR 규제 심사 프레임워크를, Herdiana Drug Design으로 규제·데이터·인력 번역 장벽을, Ali Drug Development Research으로 algorithmic transparency를 제시했다면, 오늘은 Oo J Clinical Pharmacology으로 AI/ML analytics가 dose selection·safety evaluation·durability prediction에 convergence되는 구체적 regulatory integration을(규제+AI 수렴), Shahzad Clinical Pharmacology으로 FDA CGT approval assessment의 구체적 수치 체계화를(규제 평가 수렴), Sheikh Annals으로 Kresladi 2026년 3월 승인이라는 구체적 제품화를(규제→제품 수렴) 동시에 제시한다. Translating(9/30) → AI/ML regulatory integration + evidence assessment + product approval Converging(10/03).

실무 함의: 규제 기획팀에서 Oo et al.의 AI/ML regulatory analytics 분석을 참조하여 규제 전략을 수립해야 한다.

*출처: [Oo FDA Platform AI Analytics J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Assessment Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/), [Sheikh Kresladi LAD-I FDA Approval Annals of Medicine 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/)*

*#FDA #Regulation #Oo #JClinicalPharmacology #PlatformAligned #AIML #Analytics #DoseSelection #SafetyEvaluation #DurabilityPrediction #Shahzad #ClinicalPharmacology #OrphanDesignation #ExpeditedPathway #SingleStudy #SurrogateEndpoints #PMR #PMC #Sheikh #AnnalsOfMedicine #Kresladi #LADI #ITGB2 #March2026 #GeneTherapy #ConvergingDay #RegulatoryIntegration #ProductApproval #PlatformRegulation #BiomedicalAI #DailyReport*

---

### Post 7: Spatial Transcriptomics — Platform Benchmarking × Pan-Cancer Niche Analysis: Converging

🗺️ **[Spatial Transcriptomics] Cervilla et al.로 spatial transcriptomics 5 platforms benchmarking — Visium v1/v2/HD + Xenium + CosMx + FFPE clinical samples + head-to-head comparison + RNA-protein decoupling (Genome Biology 2026) + Li et al.로 pan-cancer spatial niche — 12 cancer types 373 samples 56 LCPs + Niche_4(macrophage+tumor) poor prognosis + Niche_11(macrophage+immune) better survival (Cell Reports Medicine 2026) + Wen et al.로 spatial transcriptomics in cancer — tumorigenesis·diagnosis·therapeutics comprehensive review (Cell Death Discovery 2026): spatial transcriptomics Converging(수렴) 동시 확인**

Spatial transcriptomics의 **5개 플랫폼 head-to-head benchmarking + pan-cancer niche survival analysis(Converging)**가 출처에서 동시에 확인된다[15][16][17].

Sergi Cervilla et al.(Genome Biology 2026)의 연구는 5개 공간 전사체 플랫폼의 기술적 성능을 비교한다[15]. Visium v1, Visium v2/CytAssist, Visium HD, Xenium, CosMx를 동일한 FFPE human tumor sections에서 head-to-head comparison한다. sequencing-based와 imaging-based 플랫폼을 same samples에서 직접 비교한다. transcript·UMI detection, gene-histology concordance, cell type recovery를 평가하며, Visium v2의 targeted protein panel과 RNA profiles 통합을 수행한다. RNA-protein decoupling과 spatial heterogeneity를 확인했다. Xenium Multi-Tissue(377 genes)와 Xenium Prime(5,000 genes)의 first same-sample comparison을 수행했다.

Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종 373개 검체에서 56개 지역 세포 프로그램(LCPs)과 13개 반복 niches를 분석한다[16]. Niche_4(macrophage + tumor cell)는 poor prognosis와 immunotherapy resistance와 연관되며, Niche_11(macrophage + immune cell)은 better survival과 treatment response와 연관된다. ligand-receptor analysis로 niche-shared와 niche-specific interactions를 확인했다.

Qiang Wen et al.(Cell Death Discovery 2026)의 review는 공간 전사체의 종양学研究 적용을 종합한다[17]. tumorigenesis, diagnosis, therapeutics의 세 가지 차원에서 적용을 분석한다. malignant transformation, immune escape, drug resistance에서의 역할을 정리하며, precision cancer diagnosis와 targeted therapy 개발에서의 잠재력을 논의한다.

9월 30일 Translating(Zhang SCLC 600K cells + Li pan-cancer 56 LCPs + Gao gastric cancer) vs 오늘의 차별점: 9/30이 Zhang Cell Reports Medicine으로 SCLC 75 patients 600K cells + LNM + PIHs-1을, Li Cell Reports Medicine으로 pan-cancer 56 LCPs + Niche_4/Niche_11 survival predictors를, Gao Nature Communications으로 gastric cancer LAR + TLS를 제시했다면, 오늘은 Cervilla Genome Biology으로 spatial transcriptomics 5개 플랫폼 head-to-head benchmarking이라는 기술적 수렴을(플랫폼 수렴), 같은 Li Cell Reports Medicine에서 Niche_4/Niche_11의 구체적 생존 예측력을(생물학적 수렴), Wen Cell Death Discovery으로 tumorigenesis→diagnosis→therapeutics comprehensive review를(임상 수렴) 동시에 제시한다. Translating(9/30) → platform benchmarking + biological validation + clinical review Converging(10/03).

실무 함의: 면역종양학 연구팀에서 Cervilla et al.의 플랫폼 benchmark 결과를 참조하여 spatial transcriptomics 플랫폼 선택 기준을 수립해야 한다.

*출처: [Cervilla Spatial Platforms Benchmarking Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Li Pan-Cancer Spatial Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Wen Spatial Transcriptomics Cancer Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/)*

*#SpatialTranscriptomics #Cervilla #GenomeBiology #Benchmarking #Visium #Xenium #CosMx #FFPE #HeadToHead #RNAProteinDecoupling #Li #PanCancer #CellReportsMedicine #56LCPs #Niche4 #Niche11 #Macrophage #Tumor #Prognosis #Wen #CellDeathDiscovery #Cancer #Tumorigenesis #Diagnosis #Therapeutics #ConvergingDay #PlatformComparison #SurvivalPredictor #ImmuneMicroenvironment #BiomedicalAI #DailyReport*

---

### Post 8: 오늘의 요약 — Converging(수렴) Day 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

10/03(Converging)의 핵심: Translating(9/30) + Embedding(9/29)된 기술들이 **동시적 수렴 검증(Regulatory-grade monitoring × Clinical validation × Head-to-head benchmarking × AI/ML regulatory integration)을 경험하며, 기술의 실용성이 다차원적으로 확인되는 수렴의 날**이었다.

**1. CRISPR Global Clinical Trajectory + Regulatory-Grade Monitoring(Şahin Molecular Therapy 2026 + Freedman Nature Reviews Genetics 2026)**: ClinicalTrials.gov+EUCTR注册的 2026년 9월 기준update 글로벌 임상 시험 trajectory와 nucleotides→organism whole-scale regulatory-grade monitoring toolkit이 동시에 확인되었다[1][2].

**2. TNIK Inhibitor Phase IIa Efficacy Validation(Yoo BJC Reports 2026)**: AI로 설계된 TNIK inhibitor가 IPF 환자에서 Phase IIa efficacy를 확인했으며, AI-derived molecules의 human testing 진입 가능성을 입증했다 — 임상 validation 수렴이다[4].

**3. AlphaFold Oligomeric 4,700+ Proteins 검증(Lin Protein Science 2026)**: AlphaFold2-Multimer와 AlphaFold3의 oligomeric state prediction 정확도를 4,700개 이상의 단백질에서 검증했으며, training data dependency boundary를 제시했다 — 구조 예측 검증 수렴이다[7].

**4. SCMBench 23 Methods Benchmarking(Wang Nature Communications 2026)**: foundation models가 domain-specific models보다 낮은 성능을 실증했으며, lightweight adaptation strategy로 FM 성능 향상을 제시했다 — FM vs DM 검증 수렴이다[8].

**5. FDA AI/ML Regulatory Analytics Convergence(Oo J Clinical Pharmacology 2026)**: AI/ML analytics가 dose selection·safety evaluation·durability prediction에 convergence되는 regulatory integration이 확인되었다 — 규제+AI 수렴이다[12].

**6. Spatial 5 Platforms Head-to-Head Benchmarking(Cervilla Genome Biology 2026)**: Visium/Xenium/CosMx 등 5개 플랫폼의 FFPE clinical samples에서 head-to-head comparison이 수행되었으며, RNA-protein decoupling과 spatial heterogeneity가 확인되었다 — 플랫폼 기술 수렴이다[15].

10월 4일 전망: Converging된 기술들의 다차원적 수렴 검증이 핵심变量. 특히 TNIK Phase IIa의 broader validation, Cervilla benchmarking의 prospective validation, Freedman monitoring toolkit의 regulatory adoption이 관전이다.

*출처: [Şahin CRISPR Global Trajectory Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/), [Freedman Genome Editing Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Chakraborty CRISPR Casgevy Landscape Trends Biotechnology 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/), [Yoo TNIK Inhibitor BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/), [Mao AI Drug Discovery Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Cai Preclinical AI Pipeline Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Lin AlphaFold Oligomeric Protein Science 2026](https://consensus.app/papers/details/cff9b03d33d85cdf8d04f175b025a42c/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Sarti AlphaFold Arity Map Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/), [Ji CAPTAIN Multimodal Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Cen Single-Cell Spatial MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/), [Oo FDA Platform AI J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Clinical Pharmacology 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/), [Sheikh Kresladi Annals of Medicine 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/), [Cervilla Spatial Benchmarking Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/), [Li Pan-Cancer Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Wen Spatial Transcriptomics Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/)*

*#ConvergingDay #Summary #Şahin #CRISPR #GlobalTrajectory #Freedman #Monitoring #GenomeEditing #Yoo #TNIK #PhaseIIa #Lin #AlphaFold #OligomericState #Wang #SCMBench #FoundationModel #DomainSpecific #Sarti #ArityMap #Ji #CAPTAIN #Multimodal #Cen #SpatialOmics #Oo #FDA #AIAnalytics #Shahzad #CGT #Sheikh #Kresladi #Cervilla #Benchmarking #GenomeBiology #Li #Niche4 #Niche11 #Wen #Converging #ClinicalValidation #Benchmarking #RegulatoryGrade #BiomedicalAI #DailyReport*

---

## Sources

[1] [Şahin et al. — The landscape and trajectory of global CRISPR therapeutics. Molecular Therapy. Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/)
[2] [Freedman et al. — Monitoring Biological Effects of Somatic Cell Genome Editing. Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/)
[3] [Chakraborty et al. — CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape. Trends in Biotechnology 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)
[4] [Yoo et al. — Precision oncology in the age of AI: lessons from AI-driven drug discovery and clinical translation. BJC Reports 2026](https://consensus.app/papers/details/3061bab99a9351b297c698ef342d7f34/)
[5] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)
[6] [Cai et al. — From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery. Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/)
[7] [Lin et al. — When can AlphaFold predict the oligomeric states of proteins? Protein Science 2026](https://consensus.app/papers/details/cff9b03d33d85cdf8d04f175b025a42c/)
[8] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)
[9] [Sarti et al. — Fold or flop: quality assessment of AlphaFold predictions on whole proteomes. Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/)
[10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)
[11] [Cen et al. — Single-Cell and Spatial Omics: Methods and Applications. MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)
[12] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)
[13] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology & Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bc9b9863f1aabca040/)
[14] [Sheikh et al. — Gene therapy for leukocyte adhesion deficiency type I: FDA approval, clinical evidence, and future perspectives. Annals of Medicine and Surgery 2026](https://consensus.app/papers/details/f2f27f7392e05d9693a11da0cb87b29d/)
[15] [Cervilla et al. — A technical comparison of spatial transcriptomics platforms across six cancer types. Genome Biology 2026](https://consensus.app/papers/details/cf934161d7415209a856d6484f37f754/)
[16] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)
[17] [Wen et al. — Spatial transcriptomics in cancer research: insights into tumorigenesis, diagnosis and therapeutics. Cell Death Discovery 2026](https://consensus.app/papers/details/c7d9a4c29e4253c5b8ee0b203b998107/)